The Development and Validation of a Measure of Health-Related Quality of Life for Non-Hodgkin’s Lymphoma: The Functional Assessment of Cancer Therapy—Lymphoma (FACT-Lym)

Abstract

Background. The individual concerns of non-Hodgkin’s lymphoma (NHL) patients require identification and assessment during clinical research proposing to measure patients’ outcomes. The FACT-Lym was developed as part of the FACIT measurement system to address health-related quality-of-life (HRQL) issues for NHL patients.Patients and Methods. Items for the FACT lymphoma subscale (LymS) were generated from healthcare provider interviews, published literature, and content validity patient interviews. The FACT-Lym was validated on a sample of 84 NHL patients, with additional measures at baseline (T1), 3–7 days (T2), and 8–12 weeks (T3).Results. Item correlations, expert relevance ratings, and patient input on content shortened the initial 22-item LymS to 15 items. The validation sample included 56% female, 76.2% white, 60% indolent disease, and 85% receiving treatment. Internal consistency coefficients for the 15-item LymS (.79, .85, and .84 T1–T3) and test-retest stability (.84) indicated good reliability. Correlations between LymS and SF-36 physical (r=.62) and mental (r=.48) summary scores reflect concurrent validity. Responsiveness to ECOG performance status and treatment status exceeded established FACT subscale scores. The FACT-LymS differentiated patients’ retrospective ratings of change in each of the three groups (better; unchanged; worse),P<0.001.Conclusions. These results support the validity of the FACT-Lym and suggest it will be a useful targeted endpoint in NHL clinical research.

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

“…Clinically meaningful improvement was defi ned as a 5-point or greater increase from baseline, and worsening was defi ned as a 5-point or greater decrease from baseline. [23][24][25] Safety was analysed in patients who received at least one dose of study drug. An independent data monitoring committee monitored safety on a periodic basis.…”

The Myeloma Patient Outcome Scale is the first quality of life tool developed for clinical use and validated in patients with follicular lymphoma

“…14,23 Of critical importance to greater integration of HRQOL in the clinical care of haematological cancer patients is the availability of valid and reliable tools, sensitive to specific disease-related outcomes, yet brief, and acceptable to patients and clinicians. 15 This is the first study to demonstrate the validity and reliability of a HRQOL measure for use in patients with FL as a distinct patient group. Although the MyPOS was originally developed for use in patients with myeloma, similarities between the two diseases and a lack of FL-specific tools, led us to validate the MyPOS in FL.…”

“…Routine monitoring of HRQOL may be particularly beneficial in the care of these patients, helping to support palliation of symptoms and minimise the cumulative negative effects of treatment and disease on HRQOL . Of critical importance to greater integration of HRQOL in the clinical care of haematological cancer patients is the availability of valid and reliable tools, sensitive to specific disease‐related outcomes, yet brief, and acceptable to patients and clinicians …”

Health-related quality of life in patients with indolent and aggressive non-Hodgkin lymphoma

“…The instrument FACT-Lym (Hlubocky, Webster, Cashy, Beaumont, & Cella, 2013) complements the FACT-G with a list of symptoms specific for lymphoma. It was also developed in three steps: item generation, item reduction, and construction of the measurement.…”